{"contentid": 488567, "importid": NaN, "name": "March & April 2021 pharmaceutical M&A round-up", "introduction": "Some of biopharma's biggest companies announced acquisitions in March and April.", "content": "<p>Some of biopharma's biggest companies announced acquisitions in March and April.</p>\n<p>As well as the likes of Pfizer (NYSE: PFE) and Amgen (Nasdaq: AMGN), smaller drugmakers and other players in the drug development ecosystem bought companies.</p>\n<p>Our table below provides the details:</p>\n<table class=\"maTable maTableMonthly\" border=\"0\" cellspacing=\"0\" cellpadding=\"10\">\n<thead>\n<tr>\n<th><strong>Company</strong></th>\n<th><strong>Takeover&nbsp;candidate</strong></th>\n<th><strong>Value</strong></th>\n<th><strong>Why?</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/kartesia-acquires-100-stake-in-adl-biopharma\" rel=\"follow\">Kartesia</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/kartesia-acquires-100-stake-in-adl-biopharma\" rel=\"follow\">ADL Biopharma</a></td>\n<td>12 million-euros ($14.6 million) for remaining stake</td>\n<td>To help ADL become the preferred development and production partner for companies in growing end-markets such as alternative bio-based food, cosmetics and healthcare products</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/amgen-replenishes-its-pipeline-with-1-9-billion-acquisition\" rel=\"follow\">Amgen</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/amgen-replenishes-its-pipeline-with-1-9-billion-acquisition\" rel=\"follow\">Five Prime Therapeutics</a></td>\n<td>$1.9 billion</td>\n<td>To strengthen Amgen's oncology portfolio with a promising late-stage, first-in-class global asset to treat gastric cancer (bemarituzumab)</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/takeda-exercises-option-to-buy-maverick\" rel=\"follow\">Takeda</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/takeda-exercises-option-to-buy-maverick\" rel=\"follow\">Maverick Therapeutics</a></td>\n<td>Exercising of an option to acquire Maverick for a pre-negotiated upfront payment, previously reported as $125 million, as well as potential development and regulatory milestones totaling up to $525 million</td>\n<td>To add Maverick's COBRA platform to Takeda's oncology portfolio, providing a new conditional bioengineering approach to advance redirected immunotherapies against solid tumors</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/grifols-acquires-remaining-56-of-the-us-biopharma-gigagen\" rel=\"follow\">Grifols</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/grifols-acquires-remaining-56-of-the-us-biopharma-gigagen\" rel=\"follow\">GigaGen</a></td>\n<td>Remaining 56% share capital for $80 million</td>\n<td>To&nbsp;further strengthen Grifols' innovation strategy</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/amgen-bags-15-pgdh-as-it-rides-in-with-a-bid-for-rodeo-therapeutics\" rel=\"follow\">Amgen</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/amgen-bags-15-pgdh-as-it-rides-in-with-a-bid-for-rodeo-therapeutics\" rel=\"follow\">Rodeo</a></td>\n<td>$55 million upfront plus milestones potentially worth up to an additional $666 million</td>\n<td>Rodeo's 15-PGDH program is seen as a strong strategic fit with Amgen's inflammation portfolio</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/piramal-to-acquire-100-stake-in-hemmo-pharmaceuticals\" rel=\"follow\">Piramal</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/piramal-to-acquire-100-stake-in-hemmo-pharmaceuticals\" rel=\"follow\">Hemmo Pharmaceuticals</a></td>\n<td>7.75 billion rupees ($105.6 million) and earn-outs linked to achievement of milestones</td>\n<td>To mark PPS&rsquo; foray into the development and manufacturing of peptide active pharmaceutical ingredients, a capability that complements PPS&rsquo; existing service offering</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/sterling-pharma-solutions-confirms-acquisition-of-adc-bio\" rel=\"follow\">Sterling Pharma Solutions</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/sterling-pharma-solutions-confirms-acquisition-of-adc-bio\" rel=\"follow\">ADC Biotechnology</a></td>\n<td>&nbsp;Undisclosed</td>\n<td>To jointly establish a center of excellence for bioconjugation and ADC development and manufacturing services</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/sanofi-snaps-up-us-biotech-to-expand-i-o-portfolio\" rel=\"follow\">Sanofi</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/sanofi-snaps-up-us-biotech-to-expand-i-o-portfolio\" rel=\"follow\">Tidal Therapeutics</a></td>\n<td>$160 million upfront and up to $310 million on the achievement of certain milestones</td>\n<td>To&nbsp;expand Sanofi&rsquo;s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/tango-therapeutics-to-go-public-via-merger-with-bctg-acquisition\" rel=\"follow\">Tango Therapeutics</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/tango-therapeutics-to-go-public-via-merger-with-bctg-acquisition\" rel=\"follow\">Boxer Capital</a></td>\n<td>Reverse merger</td>\n<td>To provide Tango with the capital needed to further develop its pipeline</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/sparingvision-expands-ocular-disease-pipeline-with-buy-of-gamut-therapeutics\" rel=\"follow\">SparingVision</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/sparingvision-expands-ocular-disease-pipeline-with-buy-of-gamut-therapeutics\" rel=\"follow\">GAMUT Therapeutics</a></td>\n<td>Undisclosed</td>\n<td>To advance therapies in&nbsp;retinitis pigmentosa and&nbsp;other retinal diseases</td>\n</tr>\n<tr>\n<td><a href=\"https://www.thepharmaletter.com/article/pfizer-expands-anti-infectives-pipeline-with-acquisition\" rel=\"follow\">Pfizer</a></td>\n<td><a href=\"https://www.thepharmaletter.com/article/pfizer-expands-anti-infectives-pipeline-with-acquisition\" rel=\"follow\">Amplyx Pharmaceuticals</a></td>\n<td>Undisclosed</td>\n<td>To strengthen Pfizer's pipeline in&nbsp;new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections</td>\n</tr>\n</tbody>\n</table>\n<p>&nbsp;</p>", "date": "2021-05-07 15:02:00", "meta_title": NaN, "meta_keywords": "million, Amgen, Therapeutics, April, March, companies, development, biopharma, milestones, Maverick, pharmaceutical, round-up, biggest, announced, portfoli", "meta_description": "Some of biopharma's biggest companies announced acquisitions in March and April.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-07 12:13:59", "updated": "2021-05-07 15:03:57", "access": NaN, "url": "https://www.thepharmaletter.com/article/march-april-2021-pharmaceutical-m-a-round-up", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merger-large.jpg", "image2id": "merger-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": NaN, "topic_tag": "Companies, mergers and acquisitions", "geography_tag": NaN, "company_tag": "Amgen, Pfizer, Sanofi, Takeda", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-07 15:02:00"}